
Persephone Biosciences crafts microbial drugs to fight cancer using AI and gut microbiome analysis.
Persephone Biosciences, founded with the mission to end cancer through innovative biotherapeutic solutions, leverages the gut microbiome to develop treatments that modulate microbial metabolism. Utilizing advanced systems and synthetic biology, the company aims to understand and manipulate the complexities of the microbiome to prevent and cure diseases. Their primary focus is on creating live biotherapeutic products that can significantly impact disease progression, therapeutic response, nutrition, and longevity.
Notable figures affiliated with Persephone Biosciences include leading scientists and biotech investors who support its groundbreaking research. The company has achieved significant milestones in the development of AI-driven microbial drugs designed to combat cancer. Through its pioneering approach, Persephone Biosciences has made a substantial impact on the field of microbiome research and its application in disease treatment, positioning itself as a key player in the biotech industry.

Petri Bio
petribio.com

DeepBiome Therapeutics

Serinus Biosciences
serinus.bio

MarvelBiome
marvelbiome.com

Parallel Bio
parallel.bio

Output Biosciences
outputbio.com

Biosortia Microbiomics
biosortia.com

Solarea Bio
solareabio.com

Vedanta Biosciences
vedantabio.com

Seres Therapeutics

Vibe Bio
vibebio.com

Resilient Biotics

Pragma Biosciences
pragmabio.com

Vulcan Biologics

Microbiome Therapeutics
Companies similar to Persephone Biosciences include Petri Bio, DeepBiome Therapeutics, Serinus Biosciences and MarvelBiome.
Persephone Biosciences was founded in 2017.
Persephone Biosciences' headquarters is located in San Diego, CA, US.
Persephone Biosciences' most recent funding round was for $15M (USD) in July 2022.
As of Jul 19, 2022, Persephone Biosciences has raised a total of $15.2M (USD).
Persephone Biosciences has 17 employees as of Feb 5, 2024.